Literature DB >> 30639828

In vivo conversion of astrocytes to oligodendrocyte lineage cells in adult mice demyelinated brains by Sox2.

Sahar Farhangi1, Samaneh Dehghan1, Mehdi Totonchi2, Mohammad Javan3.   

Abstract

Sox2 transcription factor has been frequently used for reprograming starting cells to neural progenitor/stem cells. In vivo administration of Sox2 in the adult mouse brain reprogrammed the transduced astrocytes to neurons. In searching for adequate cell source for repairing the myelin insults, here, we studied the possible conversion of astrocytes to oligodendrocyte lineage cells by Sox2, while an extensive demyelination exists in animal brain. Lentiviral particles expressing Sox2-GFP were injected into the corpora callosa of animals fed with cuprizone diet for 12 weeks. Transduced cells were mainly astrocytes that changed their fate to oligodendrocyte lineage cells by time. For further conformation astrocytes received the vector in culture and then transplanted to the animal brains. Tracing the fate of transplanted cells showed their conversion to oligodendrocyte lineage cells. In vitro transduced cell were also maintained in the oligodendrocyte progenitor cell (OPC) induction medium. Produced OPC-like cells were positive for specific markers. This study provides a new strategy for endogenous production of myelinating cells. After optimizing the experimental conditions for safety and feasibility, this approach may contribute into future cell based therapies in patients with white matter insults as like as those with multiple sclerosis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  In vivo conversion; Myelin repair; Neural progenitors; Oligodendrocyte progenitor cell; Reactive astrocytes; Sox2 transcription factor

Mesh:

Substances:

Year:  2019        PMID: 30639828     DOI: 10.1016/j.msard.2018.12.041

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

1.  HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM).

Authors:  Farzaneh Sharifzad; Soura Mardpour; Saeid Mardpour; Esmaeil Fakharian; Adeleh Taghikhani; Amirhossein Sharifzad; Sahar Kiani; Yasaman Heydarian; Marek J Łos; Zahra Azizi; Saeid Ghavami; Amir Ali Hamidieh; Marzieh Ebrahimi
Journal:  Int J Mol Sci       Date:  2020-03-25       Impact factor: 5.923

Review 2.  Cellular Reprogramming and Its Potential Application in Alzheimer's Disease.

Authors:  Chao Zhou; Wanyan Ni; Taiyang Zhu; Shuyu Dong; Ping Sun; Fang Hua
Journal:  Front Neurosci       Date:  2022-04-07       Impact factor: 5.152

3.  EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes.

Authors:  Xinyu Liu; Conghui Li; Jiao Li; Lesi Xie; Zeng Hong; Kang Zheng; Xiaofeng Zhao; Aifen Yang; Xiaofeng Xu; Huaping Tao; Mengsheng Qiu; Junlin Yang
Journal:  Mol Med       Date:  2022-05-04       Impact factor: 6.376

Review 4.  Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?

Authors:  Laura Reiche; Patrick Küry; Peter Göttle
Journal:  Cells       Date:  2019-12-07       Impact factor: 6.600

5.  Regionally diverse astrocyte subtypes and their heterogeneous response to EAE.

Authors:  Malte Borggrewe; Corien Grit; Ilia D Vainchtein; Nieske Brouwer; Evelyn M Wesseling; Jon D Laman; Bart J L Eggen; Susanne M Kooistra; Erik W G M Boddeke
Journal:  Glia       Date:  2020-12-17       Impact factor: 7.452

Review 6.  Direct Conversion to Achieve Glial Cell Fates: Oligodendrocytes and Schwann Cells.

Authors:  Wonjin Yun; Yong Jun Kim; Gabsang Lee
Journal:  Int J Stem Cells       Date:  2022-02-28       Impact factor: 2.500

7.  Ethyl Pyruvate-Derived Transdifferentiation of Astrocytes to Oligodendrogenesis in Cuprizone-Induced Demyelinating Model.

Authors:  Yan He; Jun An; Jun-Jun Yin; Qiang Miao; Ruo-Xuan Sui; Qing-Xian Han; Zhi-Bin Ding; Jian-Jun Huang; Cun-Gen Ma; Bao-Guo Xiao
Journal:  Neurotherapeutics       Date:  2020-11-02       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.